Complete radiological response to first-line regorafenib in a patient with abdominal relapse of mutated GIST

Complete radiological response to first-line regorafenib in a patient with abdominal relapse of mutated GIST

Up to 13% of KIT and PDGFRA wild-type (WT) gastrointestinal stromal tumours (GIST) harbour a BRAF mutation, mostly involving the exon 15 V600E hot spot. Even if BRAF mutation is recognized as druggable target in other solid tumours, currently advanced BRAF -mutant GIST share the same therapeutical a...

Full description

Bibliographic Details
Main Authors: Margherita Nannini, Di Scioscio Valerio, Elisa Gruppioni, Annalisa Altimari, Benedetta Chiusole, Maristella Saponara, Maria Abbondanza Pantaleo, Antonella Brunello
Format: Article
Language:English
Published: SAGE Publishing 2020-06-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284820927305

Internet

https://doi.org/10.1177/1756284820927305

Similar Items